lomustine has been researched along with Recrudescence in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine." | 9.41 | Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). ( Bergo, E; Brandes, AA; Caccesse, M; Daniele, B; De Salvo, GL; Del Bianco, P; Eoli, M; Ibrahim, T; Lolli, I; Lombardi, G; Magni, G; Pace, A; Pasqualetti, F; Rizzato, S; Rudà, R; Zagonel, V, 2021) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 9.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 7.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "To the authors' knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma (AO) and oligoastrocytoma (AOA) that was recurrent after surgery and standard radiotherapy." | 7.72 | Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. ( Brandes, AA; Coria, B; Danieli, D; Ermani, M; Gardiman, M; Iuzzolino, P; Pasetto, LM; Talacchi, A; Tosoni, A; Vastola, F, 2004) |
| "Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway." | 6.94 | Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ( Campone, M; Chinot, O; Clement, PM; DeGroot, J; Donnet, V; El-Hashimy, M; Gan, H; Gil-Gil, MJ; Idbaih, A; Mason, W; Mills, D; Pineda, E; Raizer, J; Rosenthal, M; Wen, PY, 2020) |
| "We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine." | 6.39 | Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. ( Knowles, SR; Poldre, P; Shapiro, L; Shear, NH, 1996) |
| "The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine." | 5.41 | Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). ( Bergo, E; Brandes, AA; Caccesse, M; Daniele, B; De Salvo, GL; Del Bianco, P; Eoli, M; Ibrahim, T; Lolli, I; Lombardi, G; Magni, G; Pace, A; Pasqualetti, F; Rizzato, S; Rudà, R; Zagonel, V, 2021) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 5.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| "80 patients with resistant or relapsing multiple myeloma received a combination of vincristine, cyclophosphamide, lomustine, melphalan and methylprednisolone (MOCCA) as a second-line chemotherapy." | 5.07 | Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group. ( , 1992) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 3.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "To the authors' knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma (AO) and oligoastrocytoma (AOA) that was recurrent after surgery and standard radiotherapy." | 3.72 | Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. ( Brandes, AA; Coria, B; Danieli, D; Ermani, M; Gardiman, M; Iuzzolino, P; Pasetto, LM; Talacchi, A; Tosoni, A; Vastola, F, 2004) |
| "Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway." | 2.94 | Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ( Campone, M; Chinot, O; Clement, PM; DeGroot, J; Donnet, V; El-Hashimy, M; Gan, H; Gil-Gil, MJ; Idbaih, A; Mason, W; Mills, D; Pineda, E; Raizer, J; Rosenthal, M; Wen, PY, 2020) |
| "Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses." | 2.70 | Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). ( Bennett, JM; Glick, JH; Habermann, TM; Leong, T; Neiman, RS; Oken, MM; Schuster, S; Wiernik, PH, 2001) |
| "Although initial treatment of Hodgkin's disease induces a complete remission in most patients, approximately 50% of patients with advanced disease will not achieve a complete remission or will relapse following the first complete remission." | 2.67 | CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. ( Ammendolia, I; Babini, L; Barbieri, E; Bendandi, M; Fiacchini, M; Gherlinzoni, F; Neri, S; Perini, F; Salvucci, M; Zinzani, PL, 1994) |
| " Nevertheless, regimen B resulted in significantly more leukopenic patients, septicemic episodes, and blood transfusions, and the dosage of etoposide was more often reduced in arm B than in arm A." | 2.67 | Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. ( Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Pedersen, AG; Sörenson, S, 1991) |
| "In patients with stage IV Hodgkin's disease mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) was randomly tested against MOPP alternated monthly with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)." | 2.66 | Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. ( Bonadonna, G; Santoro, A; Valagussa, P, 1986) |
| "We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine." | 2.39 | Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. ( Knowles, SR; Poldre, P; Shapiro, L; Shear, NH, 1996) |
| "Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV." | 1.48 | Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. ( Amores-Fuster, I; Blackwood, L; Finotello, R; Harper, A; Killick, DR; Maddox, TW; Mason, SL; Tanis, JB, 2018) |
| "The treatment of acute myeloid leukemia (AML) permits in a population of 25 to 60 years, a complete remission (CR) about 60 to 85% with relapse free survival at 5 years from 45 to 60%." | 1.32 | [Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol]. ( Benchekroun, S; Harif, M; Qachouh, M; Quessar, A, 2003) |
| "Intracranial Hodgkin's disease is very rare and is often a terminal event." | 1.30 | Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. ( Agarwal, V; Ashigbi, MY; Bello, J; Venkatraj, U; Wiernik, PH, 1997) |
| "Patients whose Hodgkin's disease is refractory to standard combination chemotherapy usually have a poor prognosis." | 1.29 | Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease. ( al-Katib, A; Andersen, J; Bishop, CR; Hussein, ME; Karanes, C; Khanuja, PS; Smith, MR, 1994) |
| "Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens." | 1.28 | Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. ( Bonadonna, G; Bonfante, V; Negretti, E; Santoro, A; Valagussa, P; Viviani, S, 1990) |
| "Appropriate management of Hodgkin's disease is based on both the stage of disease and the specific anatomic sites of involvement within each stage." | 1.27 | Diagnosis and management of Hodgkin's disease in the adult. ( Fuller, LM; Hagemeister, FB, 1983) |
| "Between 1967 and 1977, 48 patients with Hodgkin's disease under 16-years-old were treated with MOPP chemotherapy alone at the Uganda Cancer Institute because radiotherapy facilities are not available." | 1.26 | Childhood Hodgkin's disease in Uganda: a ten year experience. ( Katongole-Mbidde, E; Kiire, C; Lwanga, SK; Magrath, I; Olweny, CL; Ziegler, JL, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (36.59) | 18.7374 |
| 1990's | 10 (24.39) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 7 (17.07) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenthal, M | 1 |
| Clement, PM | 1 |
| Campone, M | 1 |
| Gil-Gil, MJ | 1 |
| DeGroot, J | 1 |
| Chinot, O | 1 |
| Idbaih, A | 1 |
| Gan, H | 1 |
| Raizer, J | 1 |
| Wen, PY | 1 |
| Pineda, E | 1 |
| Donnet, V | 1 |
| Mills, D | 1 |
| El-Hashimy, M | 1 |
| Mason, W | 1 |
| Lombardi, G | 2 |
| Del Bianco, P | 1 |
| Brandes, AA | 3 |
| Eoli, M | 2 |
| Rudà, R | 2 |
| Ibrahim, T | 1 |
| Lolli, I | 2 |
| Rizzato, S | 2 |
| Daniele, B | 2 |
| Pace, A | 2 |
| Pasqualetti, F | 2 |
| Caccesse, M | 1 |
| Bergo, E | 1 |
| Magni, G | 2 |
| De Salvo, GL | 2 |
| Zagonel, V | 2 |
| Tanis, JB | 1 |
| Mason, SL | 1 |
| Maddox, TW | 1 |
| Blackwood, L | 1 |
| Killick, DR | 1 |
| Amores-Fuster, I | 1 |
| Harper, A | 1 |
| Finotello, R | 1 |
| Maybury, B | 1 |
| Kimpton, G | 1 |
| Otton, S | 1 |
| Faedi, M | 1 |
| Bellu, L | 1 |
| Pambuku, A | 1 |
| Farina, M | 1 |
| Indraccolo, S | 1 |
| Gardiman, MP | 1 |
| Soffietti, R | 1 |
| Fewer, D | 1 |
| Wilson, CB | 1 |
| Boldrey, EB | 1 |
| Enot, JK | 1 |
| Pavlů, J | 1 |
| Auner, HW | 1 |
| Ellis, S | 1 |
| Szydlo, RM | 1 |
| Giles, C | 3 |
| Contento, A | 1 |
| Rahemtulla, A | 2 |
| Apperley, JF | 1 |
| Naresh, K | 2 |
| MacDonald, DH | 1 |
| Kanfer, EJ | 2 |
| Brada, M | 1 |
| Stenning, S | 1 |
| Gabe, R | 1 |
| Thompson, LC | 1 |
| Levy, D | 1 |
| Rampling, R | 1 |
| Erridge, S | 1 |
| Saran, F | 1 |
| Gattamaneni, R | 1 |
| Hopkins, K | 1 |
| Beall, S | 1 |
| Collins, VP | 1 |
| Lee, SM | 1 |
| Fahey, CE | 1 |
| Milner, RJ | 1 |
| Barabas, K | 1 |
| Lurie, D | 1 |
| Kow, K | 1 |
| Parfitt, S | 1 |
| Lyles, S | 1 |
| Clemente, M | 1 |
| Ramzi, M | 1 |
| Mohamadian, M | 1 |
| Vojdani, R | 1 |
| Dehghani, M | 1 |
| Nourani, H | 1 |
| Zakerinia, M | 1 |
| Haghighinejad, H | 1 |
| Qachouh, M | 1 |
| Quessar, A | 1 |
| Harif, M | 1 |
| Benchekroun, S | 1 |
| Tosoni, A | 1 |
| Vastola, F | 1 |
| Pasetto, LM | 1 |
| Coria, B | 1 |
| Danieli, D | 1 |
| Iuzzolino, P | 1 |
| Gardiman, M | 1 |
| Talacchi, A | 1 |
| Ermani, M | 1 |
| Schmidt, F | 1 |
| Fischer, J | 1 |
| Herrlinger, U | 1 |
| Dietz, K | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Perz, JB | 1 |
| Szydlo, R | 1 |
| O'Shea, D | 1 |
| Sanz, J | 1 |
| Chaidos, A | 1 |
| Wagner, S | 1 |
| Davis, J | 1 |
| Loaiza, S | 1 |
| Marin, D | 1 |
| Apperley, J | 1 |
| Olavarria, E | 1 |
| Lampert, I | 1 |
| Samson, D | 2 |
| MacDonald, D | 1 |
| Sutcliffe, SB | 1 |
| Economopoulos, T | 1 |
| Wrigley, PF | 1 |
| Stansfeld, AG | 1 |
| Malpas, JS | 1 |
| Mead, GM | 1 |
| Harker, WG | 1 |
| Kushlan, P | 1 |
| Rosenberg, SA | 2 |
| Bleehen, NM | 1 |
| Cooper, MR | 1 |
| Pajak, TF | 2 |
| Gottlieb, AJ | 1 |
| Glicksman, AS | 1 |
| Nissen, N | 1 |
| Richards, F | 1 |
| Bloomfield, C | 1 |
| Holland, JF | 1 |
| Tsyplenkov, VG | 1 |
| Sviridova, AV | 1 |
| Grünewald, K | 1 |
| Abbrederis, K | 1 |
| Fuller, LM | 1 |
| Hagemeister, FB | 1 |
| Hildebrand, J | 1 |
| Badjou, R | 1 |
| Collard-Ronge, E | 1 |
| Delforge, A | 1 |
| Malarme, M | 1 |
| Spiro, T | 1 |
| Sztern, B | 1 |
| Vandensteene, A | 1 |
| Stryckmans, PA | 1 |
| Smith, MR | 1 |
| Khanuja, PS | 1 |
| al-Katib, A | 1 |
| Bishop, CR | 1 |
| Andersen, J | 1 |
| Hussein, ME | 1 |
| Karanes, C | 1 |
| Brusamolino, E | 1 |
| Orlandi, E | 1 |
| Canevari, A | 1 |
| Morra, E | 1 |
| Castelli, G | 1 |
| Alessandrino, EP | 1 |
| Pagnucco, G | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Lazzarino, M | 1 |
| Zinzani, PL | 1 |
| Barbieri, E | 1 |
| Bendandi, M | 1 |
| Perini, F | 1 |
| Gherlinzoni, F | 1 |
| Neri, S | 1 |
| Ammendolia, I | 1 |
| Salvucci, M | 1 |
| Babini, L | 1 |
| Fiacchini, M | 1 |
| Shear, NH | 1 |
| Knowles, SR | 1 |
| Shapiro, L | 1 |
| Poldre, P | 1 |
| Ashigbi, MY | 1 |
| Venkatraj, U | 1 |
| Agarwal, V | 1 |
| Bello, J | 1 |
| Wiernik, PH | 2 |
| van den Bent, MJ | 1 |
| Kros, JM | 1 |
| Heimans, JJ | 1 |
| Pronk, LC | 1 |
| van Groeningen, CJ | 1 |
| Krouwer, HG | 1 |
| Taphoorn, MJ | 1 |
| Zonnenberg, BA | 1 |
| Tijssen, CC | 1 |
| Twijnstra, A | 1 |
| Punt, CJ | 1 |
| Boogerd, W | 1 |
| Brugières, L | 1 |
| Quartier, P | 1 |
| Le Deley, MC | 1 |
| Pacquement, H | 1 |
| Perel, Y | 1 |
| Bergeron, C | 1 |
| Schmitt, C | 1 |
| Landmann, J | 1 |
| Patte, C | 1 |
| Terrier-Lacombe, MJ | 1 |
| Delsol, G | 1 |
| Hartmann, O | 1 |
| Parameswaran, R | 1 |
| Boots, M | 1 |
| Littlewood, TJ | 1 |
| Mills, MJ | 1 |
| Kelsey, SM | 1 |
| Leong, T | 1 |
| Oken, MM | 1 |
| Neiman, RS | 1 |
| Habermann, TM | 1 |
| Bennett, JM | 1 |
| Schuster, S | 1 |
| Glick, JH | 1 |
| Porzig, KJ | 1 |
| Portlock, CS | 1 |
| Robertson, A | 1 |
| Livingston, RB | 1 |
| Heilbrun, LH | 1 |
| Kane, RC | 1 |
| Cohen, MH | 1 |
| Kung, FH | 1 |
| Nythan, WL | 1 |
| Cuttner, J | 1 |
| Falkson, G | 1 |
| Lanzkowsky, P | 1 |
| Del Duca, V | 1 |
| Nawabi, IU | 1 |
| Koch, K | 1 |
| Pluess, H | 1 |
| Freeman, A | 1 |
| Burgert, EO | 1 |
| Leone, LA | 1 |
| Ruymann, F | 1 |
| Patterson, RB | 1 |
| Degnan, T | 1 |
| Hakami, N | 1 |
| Holland, J | 1 |
| Olweny, CL | 1 |
| Katongole-Mbidde, E | 1 |
| Kiire, C | 1 |
| Lwanga, SK | 1 |
| Magrath, I | 1 |
| Ziegler, JL | 1 |
| Viviani, S | 1 |
| Santoro, A | 2 |
| Negretti, E | 1 |
| Bonfante, V | 1 |
| Valagussa, P | 2 |
| Bonadonna, G | 2 |
| Demina, EA | 1 |
| Kondrat'eva, NF | 1 |
| Pirogova, NA | 1 |
| Osterlind, K | 1 |
| Hansen, M | 1 |
| Hirsch, FR | 1 |
| Dombernowsky, P | 1 |
| Sörenson, S | 1 |
| Pedersen, AG | 1 |
| Hansen, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme[NCT01934361] | Phase 1 | 35 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial[NCT02926222] | Phase 2 | 119 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455] | Phase 3 | 500 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lomustine and Recrudescence
| Article | Year |
|---|---|
Management of small cell cancer: radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Mod | 1984 |
Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.
Topics: Antineoplastic Agents; Dapsone; Hidradenitis; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; | 1996 |
15 trials available for lomustine and Recrudescence
| Article | Year |
|---|---|
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Fe | 2020 |
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
Topics: Aged; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Patient Reported Outcome Measures; | 2021 |
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Female; Glioblastoma; Humans; Lomu | 2019 |
Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Lomustine; Neoplas | 1972 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cryopreservation; Cytarabine; Eto | 2012 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combin | 1984 |
CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 1994 |
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; | 2001 |
Patterns of response and relapse in chemotherapy of extensive squamous carcinoma of the lung.
Topics: Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hu | 1978 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
Topics: Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resi | 1992 |
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; | 1991 |
Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dox | 1986 |
24 other studies available for lomustine and Recrudescence
| Article | Year |
|---|---|
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2019 |
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2011 |
Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Drug Resistance, Neopla | 2011 |
[Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2003 |
Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Combined Modality Therapy; | 2004 |
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 2007 |
Prognosis of Hodgkin's disease: patients who fail to remit or who relapse after combination chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Child, Preschool; Drug Therapy, Co | 1980 |
Single agent palliative chemotherapy for end-stage Hodgkin's disease.
Topics: Adolescent; Adult; Female; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Nitrosourea Compou | 1982 |
[Evaluation of the efficacy of radiotherapy in the combined treatment of generalized Hodgkin's disease in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1984 |
[Long-term survival and fatal late relapse in acute leukaemia in adults].
Topics: Acute Disease; Adolescent; Adult; Cyclophosphamide; Female; Humans; Leukemia; Lomustine; Male; Metho | 1983 |
Diagnosis and management of Hodgkin's disease in the adult.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Ho | 1983 |
Treatment of brain giomas with high dose of CCNU and autologous bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Glioma; Hematologic Diseases; Humans; Lomustine; Nitro | 1980 |
Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Fe | 1994 |
Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dox | 1994 |
Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modalit | 1997 |
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1998 |
Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow Tra | 2000 |
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 2000 |
Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.
Topics: Adolescent; Adult; Bleomycin; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Hodgk | 1978 |
Superior vena caval obstruction due to small-cell anaplastic lung carcinoma. Response to chemotherapy.
Topics: Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Lomustine; Lung Neoplasms; Methotr | 1976 |
Childhood Hodgkin's disease in Uganda: a ten year experience.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Gynec | 1978 |
Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Et | 1990 |
[The combined therapy of stage-II lymphogranulomatosis: the effect of splenectomy and the time period for achieving full remission on treatment efficacy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; | 1991 |